• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immutep Limited - American Depositary Shares (NQ:IMMP)

    2.825 -0.105 (-3.58%)
    Streaming Delayed Price Updated: 1:45 PM EST, Dec 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Immutep Limited - American Depositary Shares

    News headline image
    SurgePays (NASDAQ: SURG) Expands Growth Strategy – New Lead-Driver to Boost Fintech Revenue – More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
    From Immutep Limited
    Via GlobeNewswire
    News headline image
    Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
    From Immutep Limited
    Via GlobeNewswire
    News headline image
    Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
    From Immutep Limited
    Via GlobeNewswire
    News headline image
    Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
    From Immutep Limited
    Via GlobeNewswire
    News headline image
    Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
    From Immutep Limited
    Via GlobeNewswire
    News headline image
    Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
    From Immutep Limited
    Via GlobeNewswire
    News headline image
    Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
    From Immutep Limited
    Via GlobeNewswire
    News headline image
    Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
    From Immutep Limited
    Via GlobeNewswire
    News headline image
    Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
    From Immutep Limited
    Via GlobeNewswire
    News headline image
    Why Did Immutep Ltd Stock Soar Recently?
    Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate. 
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
    From Immutep Limited
    Via GlobeNewswire
    News headline image
    Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
    From Immutep Limited
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.